AstraZeneca: Tagrisso Delivers Eight-Year Survival Benefit In Early-Stage EGFR-Mutated Lung Cancer

Cuts Risk Of Death By 47% In Stage II-IIIA Patients At Eight Years - Cuts Risk Of Death By 48% In Stage IB-IIIA Patients At Eight Years - 74% Of Stage II-IIIA Patients Alive At Eight Years - 79% Of Stage IB-IIIA Patients Alive At Eight Years - Final ADAURA Safety Data Show No New Safety Concerns